IBCSG 52-15 PALLAS

  • PALLAS: PALbociclib CoLlaborative Adjuvant Study:
    A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.

    • Study Chair
      Michael Gnant, MD, Vienna

      Trial Coordinators
      Poonam Jani, Dorene Polizzi

      Monitoring 
      ETOP IBCSG Partner Foundation
      Coordinating Center, Bern, Switzerland
      Phone: +41 31 511 94 00
      Fax: +41 31 511 94 01
      Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

      IBCSG Data Management Center/FSTRF
      4033 Maple Road
      Amherst, New York 14226 USA
      Phone: +1 716 834 0900
      Fax: +1 716 833 3990
      Email: This email address is being protected from spambots. You need JavaScript enabled to view it. 

      Date of Activation
      March 31, 2016

      Targeted Accrual
      4600

    ETOP IBCSG Partners Foundation
    Effingerstrasse 33
    3008 Bern, Switzerland

    Contact
    Phone: +41 31 511 94 00
    E-mail: contact@etop.ibcsg.org

    Member Login